Optimer reports positive results from second Phase III diarrhea study
The top-line analysis of data from this study shows that Prulifloxacin met the study objective of superiority to placebo in the resolution of diarrhea, measured by time to
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.
The lintuzumab Phase IIb clinical trial is a randomized, double-blind, placebo-controlled study evaluating whether the combination regimen of lintuzumab and low-dose cytarabine chemotherapy extends overall survival compared to